ArticleSchizophrenia bulletin2024
A Global, Regional, and National Burden and Quality of Care Index for Schizophrenia: Global Burden of Disease Systematic Analysis 1990-2019.
Article in Schizophrenia bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Decreased serum IGFBP-7 level is associated with cognitive impairment in first-episode drug-naïve adolescent-onset schizophrenia.Annals of general psychiatry · 2026Article
- Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation-A Narrative Review.International journal of molecular sciences · 2026Review
- Quality of care index for acute lymphoblastic leukaemia at global, regional, and national levels: a systematic analysis of the global burden of disease from 1990 to 2021.Journal of global health · 2026Article
- Disrupted Emergent Properties of the Brain in Schizophrenia: Insight From Integrated Information Decomposition of Resting State fMRI.Brain and behavior · 2026Article
- When Randomness Becomes Rigid: Dynamic Connectivity Entropy and Symptom-Linked Network Dysfunction in Schizophrenia.bioRxiv : the preprint server for biology · 2026Article
- Advances in implementation strategies for treatment adherence in schizophrenia: a narrative review.Frontiers in psychiatry · 2026Review
- Global, regional, and national burden of schizophrenia: epidemiological trends, decomposition, joinpoint analysis, and projections to 2036 based on GBD 2021.Frontiers in psychiatry · 2026Article
- Quality of care index and gender disparity ratio for stroke and its subtypes from the Global Burden of Disease Study 2021.PloS one · 2026Article
- Graph Neural Networks and Multimodal DTI Features for Schizophrenia Classification: Insights from Brain Network Analysis and Gene Expression.Neuroscience bulletin · 2025Article
- Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.Acta neuropsychiatrica · 2025Article
- Altered serum glutathione disulfide levels in acute relapsed schizophrenia are associated with clinical symptoms and response to electroconvulsive therapy.BMC psychiatry · 2025Article
- Integrated Transcriptome Analysis Reveals Novel Molecular Signatures for Schizophrenia Characterization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Global Burden of Schizophrenia Among Women of Reproductive Age from 1990 to 2021: Trends, Inequalities, and Projections to 2040.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Results of the Global Burden of Disease study for schizophrenia: trends from 1990 to 2021 and projections to 2050.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
background and hypothesisSchizophrenia is a mental disorder usually presented in adulthood that affects roughly 0.3 percent of the population. The disease contributes to more than 13 million years lived with disability the global burden of disease. The current study aimed to provide new insights into the quality of care in Schizophrenia via the implementation of the newly introduced quality of care index (QCI) into the existing data. STUDY
designThe data from the global burden of disease database was used for schizophrenia. Two secondary indices were calculated from the available indices and used in a principal component analysis to develop a proxy of QCI for each country. The QCI was then compared between different sociodemographic index (SDI) and ages. To assess the disparity in QCI between the sexes, the gender disparity ratio (GDR) was also calculated and analyzed in different ages and SDIs. STUDY
resultsThe global QCI proxy score has improved between 1990 and 2019 by roughly 13.5%. Concerning the gender disparity, along with a rise in overall GDR the number of countries having a GDR score of around one has decreased which indicates an increase in gender disparity regarding quality of care of schizophrenia. Bhutan and Singapore had 2 of the highest QCIs in 2019 while also showing GDR scores close to one.
conclusionsWhile the overall conditions in the quality of care have improved, significant disparities and differences still exist between different countries, genders, and ages in the quality of care regarding schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.